Animal model of depression

A behavioural procedure is described which may provide an animal model for some aspects of human depression. Rats or mice when forced to swim in a restricted space will rapidly cease attempts to escape and become immobile. Immobility is reduced by many clinically effective antidepressant treatments suggesting that the immobile behaviour may reflect a state of lowered mood in the animal. If so the method could be useful as a simple experimental tool for research into the biology and therapeutics of depression.     

Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine.

Lisuride (0.05 – 0.1 mg/kg), lergotrile (1 mg/kg) and bromocriptine (5 mg/kg) reduced the turnover of dopamine (DA) in rat brain, as indicated by a pronounced decrease of cerebral homovanillic acid (HVA) without appreciable changes in DA level. Time curves revealed that lisuride injected intracerebroventricularly or i.p. caused a rapid reduction of HVA lasting for a few hours, whereas after p.o. administration the decrease of HVA was delayed. Pretreatment of the rats with the microsomal enzyme inhibitor proadifen potentiated and prolonged, rather than prevented, the effect of i.p. injected lisuride on rat cerebral DA turnover. The HVA reduction obtained with lergotrile and bromocriptine was also somewhat retarded after p.o. administration; the HVA diminution seen after i.p. injection was again potentiated and prolonged by proadifen. In addition, this microsomal enzyme inhibitor prolonged and intensified, rather than prevented, the hypothermic effect of all of the 3 ergolines. It is concluded that, in the rat, the central DA agonistic activity of the ergolines studied is caused by the drugs themselves and does not require previous biotransformation into active metabolites. The retarded onset and the prolonged duration of action after oral administration is probably due to slow intestinal absorption and slow microsomal inactivation, respectively.     

Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression

In the past few years, literature has accumulated describing manifestation of seizures following administration of certain antidepressants. Such reports are of particular importance because depression is a frequent psychiatric problem associated with epilepsy. Therefore, in the view of the fact that NMDA receptor antagonists have been reported to reduce behavioural deficits and have been shown to be anticonvulsant, it was considered imperative to study their antidepressant effect using shock-induced depression model in mice. Presentation of inescapable foot shock significantly reduced ambulation and rearing in the open field arena and increased immobility duration in the FST. Pretreatment with imipramine, MK 801 and ketamine significantly prevented the effect of shock. Also, the combination of imipramine with either of the NMDA antagonists antagonised the effect of shock. Haloperidol, prazosin and ketanserin pretreatment modified the effect of these agents. These findings suggest an antidepressant effect of the NMDA receptor antagonists, and a complexity of neurotransmitter mechanisms, which are responsible for the occurrence of behavioural effects in shock-induced depression model.     

Antidepressant drugs: imipramine, mianserin and trazodone

The advent of newer antidepressant drugs (second generation) during the past two decades has provided an alternative to the use of tricyclic antidepressants in the alleviation of depression. These antidepressants have not been proven to be superior in the therapy of depression to the tricyclic antidepressants but they have been reported to cause fewer cardiac effects. Most of the reported adverse cardiac reactions elicited by antidepressant drugs are based on observations from clinical studies. The possible underlying mechanisms by which these adverse reactions arise have for the large part been proposed on the basis of clinical findings which have been extrapolated back to the known pharmacological actions of such drugs. There is a paucity of hard experimental data in this respect.     

鼠疫动物模型:经典与问题

一直以来,鼠疫菌的研究多围绕致病机制、疫苗效果评价及鼠疫治疗方案选择展开,而合理有效的鼠疫动物模型正是这些实验研究的基础与前提。研究者构建了包括小鼠、豚鼠及非人灵长类模型在内的多种动物模型,而这些模型也为人类认识、防御及治疗鼠疫菌提供了帮助,特别是一些经典动物模型沿用至今。但随着研究的深入,有些动物模型由于存在某种问题而逐渐被淘汰。本文就鼠疫菌动物模型构建以来,不同模型的优势与不足及其应用展开综述,以期为研究者提供参考。     

Binding of imipramine and cocaine to a model lipid membrane

[³H]Imipramine and [³H]cocaine were concentrated at membranes of liposomes prepared from phosphatidylcholine, cholesterol, and dicetylphosphate. This binding has an apparent dissociation constant in the micromolar range and a density close to 2 pmol/g of phosphatidylcholine. The potencies of various drugs in inhibiting the binding ot liposomes correlated only weakly with those in inhibiting the high-affinity binding of [³H]imipramine and [³H]cocaine to brain membranes. However, there was a highly significant correlation between the potencies of drugs in inhibiting binding to liposomes and their lipophilic character, indicating the involvement of hydrophobic bonding. Although the amounts of phosphatidylcholine and cholesterol in brain preparations in assays for high-affinity binding to brain membranes were in the same range as those used in our assays with liposomes, the inhibition of the high-affinity binding to brain membranes was only weakly dependent upon the lipophilicity of the inhibiting drug. These results indicate that lipophilicity is but one of the factors in the complex binding interactions between lipophilic substances and integral brain membranes. In addition, the results are in agreement with the suggestion that phosphatidylcholine and cholesterol are not the primary sites of high-affinity binding [³H]imipramine and [³H]cocaine to brain membranes, although it cannot be ruled out that these lipids have different properties in natural biological membranes and in artificial liposome membranes.     

A new motor model representing the stretch-induced force enhancement and shortening-induced force depression in skeletal muscle

A motor model that consists of two Maxwell elements with a force generator and one Voigt element is proposed in this paper. The motor model can achieve a hyperbolic force-velocity relation when we alter weight functions applied to the Maxwell elements and the force generator. Rate coefficients are introduced to determine the weight function and to improve the motor performance and the time course of the motor force. The weight functions are used as a controller of the motor. We assume that the mechanical impulse applied to the motor affects the rate coefficients and found that the amount of the mechanical impulse is related to the amount of force depression following motor shortening and to the amount of force enhancement following motor stretching. The time courses of the motor force following shortening and stretching quantitatively resemble those in other muscle experiments. The maximum energy efficiency of the motor that we obtained was 50% with an ATP hydrolysis type and 25% with an AC-DC motor type.     

Effect of imipramine on the circadian rhythm of plasma melatonin in unipolar depression

The authors took a series of 20 serum samples over a 24-hr period for measurement of melatonin in four men and six women with Major Depressive Disorder (DSM-III), at baseline (depressed) and after 4 weeks on imipramine (150-200 mg/day) after achieving clinical remission. After successful treatment with imipramine, 24-hr secretion and peak levels of melatonin were significantly higher than at baseline, with no difference in time of peak level. Testing after 2 weeks of treatment (four subjects), with only a partial or no clinical response, revealed no differences compared with baseline. The therapeutic efficacy of imipramine may be associated with an enhancement of noradrenergic activity.     

Pharmacological difference of L-dopa,apomorphine, and bromocriptine against metoclopramide

Rat prolactin was stimulated by metoclopramide and inhibited by L-dopa, apomorphine and bromocriptine. Depending on the order of administration, the efficiency of bromocriptine deviated from L-dopa and apomorphine in opposite directions. When injected into rats 15 min after metoclopramide, bromocriptine was much less effective than L-dopa and apomorphine in blocking the effect of metoclopramide on serum prolactin. When injected into rats 15 min before metoclopramide, bromocriptine was the most effective antagonist of metoclopramide action. A plausible explanation of these observations is that bromocriptine and metoclopramide are not strictly dopamine agonists and antagonists, while L-dopa and apomorphine act exclusively by a dopamine mechanism.     

Animal motor activity and cerebellar beta-adrenoreceptors after disturbance of the glucocorticoid balance

The number of divings of rats in the forced-swimming test increased after adrenalectomy and/or dexamethasone treatment. The activation of the behavior was accompanied by an increase in the density of beta-adrenoreceptors in the cerebellum of these animals. These adrenoreceptors can be a necessary link in the pathway of signal transmission that underlies the behavioral effects of glucocorticoids acting intracellularly.     

Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study.

The efficacy and tolerability of a slow-release preparation of bromocriptine (Parlodel SRO) were compared to those of conventional bromocriptine (Parlodel R) in a double blind, double dummy study of 12 hyperprolactinemic women (plasma PRL 81.3 +/- 4.73, ng/ml mean +/- SEM). For 2 weeks, the patients received 2.5 mg b.i.d. Parlodel R or 5 mg once daily Parlodel SRO; for the following 2 weeks, the dose of the drugs was doubled. The patients were then treated, in an open study, with 2.5-10 mg daily Parlodel SRO for 6 months. Both preparations caused a prompt and sharp PRL fall. Hormone levels remained inhibited over the whole month of observation with both preparations. Daily PRL profiles were very close with either drug although morning PRl levels were slightly higher during Parlodel SRO than during Parlodel R administration. Doubling the doses of the two drugs did not result in further significant lowering of PRL values. During the 6-month study with Parlodel SRO, plasma PRL further decreased and normalized in 11 of 12 patients. Clinical improvement occurred in the majority of cases. Tolerability of Parlodel SRO appeared to be better, though without statistically significant differences, than that of Parlodel R. Side effects were less important with the former compound in their number, severity and duration. In conclusion, thanks to its favourable pharmacological profile, Parlodel SRO appears to be a valuable alternative to regular bromocriptine in the management of hyperprolactinemia.